MicroRNAs in systemic rheumatic diseases

Angela Ceribelli, Bing Yao, Paul R. Dominguez-Gutierrez, Md A. Nahid, Minoru Satoh, Edward K L Chan

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression, allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis, relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible for the development of disease.

Original languageEnglish
Article number229
JournalArthritis Research and Therapy
Volume13
Issue number4
DOIs
Publication statusPublished - Jul 13 2011

Fingerprint

Rheumatic Diseases
MicroRNAs
Autoimmune Diseases
Physiological Phenomena
Body Fluids
Pathologic Processes
Saliva
Systemic Lupus Erythematosus
Disease Progression
Rheumatoid Arthritis
Therapeutics
Nucleotides
Biomarkers
RNA
Kidney
Gene Expression
Recurrence

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Ceribelli, A., Yao, B., Dominguez-Gutierrez, P. R., Nahid, M. A., Satoh, M., & Chan, E. K. L. (2011). MicroRNAs in systemic rheumatic diseases. Arthritis Research and Therapy, 13(4), [229]. https://doi.org/10.1186/ar3377

MicroRNAs in systemic rheumatic diseases. / Ceribelli, Angela; Yao, Bing; Dominguez-Gutierrez, Paul R.; Nahid, Md A.; Satoh, Minoru; Chan, Edward K L.

In: Arthritis Research and Therapy, Vol. 13, No. 4, 229, 13.07.2011.

Research output: Contribution to journalArticle

Ceribelli, A, Yao, B, Dominguez-Gutierrez, PR, Nahid, MA, Satoh, M & Chan, EKL 2011, 'MicroRNAs in systemic rheumatic diseases', Arthritis Research and Therapy, vol. 13, no. 4, 229. https://doi.org/10.1186/ar3377
Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EKL. MicroRNAs in systemic rheumatic diseases. Arthritis Research and Therapy. 2011 Jul 13;13(4). 229. https://doi.org/10.1186/ar3377
Ceribelli, Angela ; Yao, Bing ; Dominguez-Gutierrez, Paul R. ; Nahid, Md A. ; Satoh, Minoru ; Chan, Edward K L. / MicroRNAs in systemic rheumatic diseases. In: Arthritis Research and Therapy. 2011 ; Vol. 13, No. 4.
@article{e2363ebdbdf34d9f95a19000add8a2ca,
title = "MicroRNAs in systemic rheumatic diseases",
abstract = "MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression, allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis, relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible for the development of disease.",
author = "Angela Ceribelli and Bing Yao and Dominguez-Gutierrez, {Paul R.} and Nahid, {Md A.} and Minoru Satoh and Chan, {Edward K L}",
year = "2011",
month = "7",
day = "13",
doi = "10.1186/ar3377",
language = "English",
volume = "13",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - MicroRNAs in systemic rheumatic diseases

AU - Ceribelli, Angela

AU - Yao, Bing

AU - Dominguez-Gutierrez, Paul R.

AU - Nahid, Md A.

AU - Satoh, Minoru

AU - Chan, Edward K L

PY - 2011/7/13

Y1 - 2011/7/13

N2 - MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression, allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis, relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible for the development of disease.

AB - MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression, allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis, relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible for the development of disease.

UR - http://www.scopus.com/inward/record.url?scp=79960740957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960740957&partnerID=8YFLogxK

U2 - 10.1186/ar3377

DO - 10.1186/ar3377

M3 - Article

C2 - 21787439

AN - SCOPUS:79960740957

VL - 13

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 4

M1 - 229

ER -